Details of Drug-Drug Interaction
| Drug General Information (ID: DDIDFM032G) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Paclitaxel (protein-bound) | Drug Info | Elotuzumab | Drug Info | |||||
| Drug Type | Small molecule | Monoclonal antibody | |||||||
| Therapeutic Class | Antineoplastics/Mitotic Inhibitors | Antineoplastics | |||||||
| Mechanism of Paclitaxel (protein-bound)-Elotuzumab Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Increased risk of peripheral neuropathy Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Paclitaxel (protein-bound) | Elotuzumab | |||||||
| Mechanism | Peripheral neuropathy | Peripheral neuropathy | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Peripheral neuropathy | ||||||||
| Factor Description | Peripheral neuropathy is a disorder of the peripheral nerves that can cause sensory and motor symptoms, and even paralysis in severe cases. Signs and symptoms of peripheral neuropathy may include: gradual numbness, tingling or prickling in the feet or hands that can spread up the legs and arms; sharp, stinging, pricking or burning sensations; extreme sensitivity to touch; pain during activities that should not cause pain; lack of coordination and falls; muscle weakness; and paralysis if the motor nerves are affected. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage. | ||||||||